EMPOWER CLINICS INC - EPWCF STOCK NEWS

Empower Clinics Inc. (CSE:CBDT)(FRA:8EC)(OTCQB:EPWCF) announced the approval of a Management Cease Trade Order (MCTO) from the British Columbia Securities Commission due to delays in filing audited annual financial statements for the year ending December 31, 2020. The MCTO restricts trading by the CEO and CFO but does not affect other shareholders. The company anticipates filing the required documents by May 21, 2021, citing COVID-19 impacts on audits as the primary reason for the delay. Empower is committed to maintaining transparency through alternative information guidelines while awaiting the filing.

Empower Clinics Inc. (OTCQB:EPWCF) announced it will not file its annual audited financial statements for 2020 by the April 30, 2021 deadline. The delay is attributed to difficulties caused by the coronavirus pandemic, which hindered travel for audits, and the need for valuations of two recently acquired private companies, which lacked prior audit experience. The Company has applied for a Management Cease Trade Order (MCTO) to restrict trading by senior executives while it works to meet regulatory requirements.

Empower Clinics Inc. (OTCQB:EPWCF) has introduced a direct-to-consumer e-commerce platform for at-home COVID-19 saliva tests through a partnership with The Snow Agency. Customers in the U.S. can now purchase test kits with same-day shipping via kaitests.com, with Canadian options launching soon. Empower's labs can process up to 4,000 tests daily, promoting health convenience and safety. The partnership aims to boost awareness of their at-home testing solutions while supporting the economy's reopening.

Empower Clinics Inc. (EPWCF) has announced its eligibility for Depository Trust Company (DTC) services, enhancing the accessibility of its stock for U.S. investors. With this development, trading of Empower's shares on the OTC market is now simplified, likely resulting in improved trading liquidity. DTC, a subsidiary of the DTCC, facilitates electronic trading and settlement, aiding investors and brokers in the U.S. markets. Empower continues to grow its presence across North America through integrated healthcare services, including telemedicine and medical diagnostics.

Empower Clinics announced that its acquired Kai Medical Laboratory received a repeat order for 5,000 COVID-19 RT-PCR tests from two film and television productions, generating anticipated revenue exceeding $CAD 750,000. This follow-up order highlights the lab's consistent performance since its acquisition on October 6, 2020, with prior orders totaling over $CAD 1,000,000. With a plan to triple its size to meet growing demand in testing, Empower remains committed to expanding its services and product offerings across North America.

Empower Clinics has appointed Yoshi Tyler to its board of directors. Tyler, who has over 13 years of leadership experience at Pfizer, has led Kai Medical Laboratory, acquired in October 2020, to surpass initial growth forecasts. Empower aims to strengthen its integrated healthcare presence across North America. The CEO, Steven McAuley, expressed confidence in Tyler's contributions, highlighting her performance and commitment. This addition is expected to enhance the leadership team as the company continues to expand its diagnostics and healthcare services.

Empower Clinics Inc. (OTCQB: EPWCF) has announced a new partnership with Snow Agency, a top digital marketing firm, to enhance its direct-to-consumer e-commerce solutions. This collaboration aims to improve patient access to at-home diagnostics, particularly COVID-19 saliva test kits. With Snow Agency recognized as the leading U.S. digital marketing agency, the partnership is expected to increase sales and facilitate ongoing testing during the pandemic. Empower is focused on providing convenient healthcare options and maintaining a strong digital presence across North America.

Empower Clinics Inc. (OTCQB: EPWCF) reported a remarkable 460% increase in patient counts in Q1 2021 compared to Q1 2020, reaching 26,317 patients. In March 2021 alone, patients surged 388% year-on-year to 8,379. This growth underscores Empower's effective patient acquisition strategy and dedication to quality care. The company also issued 800,000 stock options priced at $0.57 CAD to service providers and a director, indicating a focus on strengthening investor relations. Empower aims to expand its clinical and digital healthcare presence across North America.